Advanced

First comprehensive tool for screening pain in Parkinson's disease : the King's Parkinson's Disease Pain Questionnaire

, ; , ; Martinez-Martin, P.; Rizos, A. M.; Wetmore, J.; Antonini, A.; Odin, P. LU ; Pal, S.; Sophia, R. and Carroll, C., et al. (2018) In European Journal of Neurology 25(10). p.1255-1261
Abstract

Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients’ ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test–retest) and diagnostic performance of the questionnaire were analysed. Results: Data... (More)

Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients’ ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test–retest) and diagnostic performance of the questionnaire were analysed. Results: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 ± 2.56 vs. 2.17 ± 1.39; P < 0.0001). The KPPQ convergent validity was high with KPPS total score (rS = 0.80) but weak or moderate with other pain assessments. Test–retest reliability was satisfactory with kappa values ≥0.65 except for item 5, Dyskinetic pains (κ = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98. After the scores of the KPPS were adapted for screening (0, no symptom; ≥1, symptom present), a good agreement was found between the KPPQ and the KPPS (ICC = 0.88). A strong correlation (rS = 0.80) between the two instruments was found. The diagnostic parameters of the KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%–98.3%. Conclusions: These results suggest that the KPPQ is a useful, reliable and valid screening instrument for pain in PD to advance patient-related outcomes.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
assessment, King's Parkinson's Disease Pain Questionnaire, pain, Parkinson's disease, screening, validation
in
European Journal of Neurology
volume
25
issue
10
pages
7 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85053007934
ISSN
1351-5101
DOI
10.1111/ene.13691
language
English
LU publication?
yes
id
6c9d7d1d-1a12-4f03-ba26-7b4603cd6171
date added to LUP
2018-10-10 10:52:50
date last changed
2019-09-17 04:40:34
@article{6c9d7d1d-1a12-4f03-ba26-7b4603cd6171,
  abstract     = {<p>Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients’ ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test–retest) and diagnostic performance of the questionnaire were analysed. Results: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 ± 2.56 vs. 2.17 ± 1.39; P &lt; 0.0001). The KPPQ convergent validity was high with KPPS total score (r<sub>S</sub> = 0.80) but weak or moderate with other pain assessments. Test–retest reliability was satisfactory with kappa values ≥0.65 except for item 5, Dyskinetic pains (κ = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98. After the scores of the KPPS were adapted for screening (0, no symptom; ≥1, symptom present), a good agreement was found between the KPPQ and the KPPS (ICC = 0.88). A strong correlation (r<sub>S</sub> = 0.80) between the two instruments was found. The diagnostic parameters of the KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%–98.3%. Conclusions: These results suggest that the KPPQ is a useful, reliable and valid screening instrument for pain in PD to advance patient-related outcomes.</p>},
  author       = {,  and ,  and Martinez-Martin, P. and Rizos, A. M. and Wetmore, J. and Antonini, A. and Odin, P. and Pal, S. and Sophia, R. and Carroll, C. and Martino, D. and Falup-Pecurariu, C. and Kessel, B. and Andrews, T. and Paviour, D. and Trenkwalder, C. and Chaudhuri, K. R.},
  issn         = {1351-5101},
  keyword      = {assessment,King's Parkinson's Disease Pain Questionnaire,pain,Parkinson's disease,screening,validation},
  language     = {eng},
  number       = {10},
  pages        = {1255--1261},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Neurology},
  title        = {First comprehensive tool for screening pain in Parkinson's disease : the King's Parkinson's Disease Pain Questionnaire},
  url          = {http://dx.doi.org/10.1111/ene.13691},
  volume       = {25},
  year         = {2018},
}